|
FR2711670B1
(fr)
|
1993-10-22 |
1996-01-12 |
Pasteur Institut |
Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
|
|
US6727230B1
(en)
*
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
|
US6207646B1
(en)
*
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US7034007B1
(en)
|
1995-06-07 |
2006-04-25 |
East Carolina University |
Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
|
|
US6825174B2
(en)
|
1995-06-07 |
2004-11-30 |
East Carolina University |
Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
|
|
US6592877B1
(en)
*
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
|
US6290969B1
(en)
*
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
|
US6238921B1
(en)
*
|
1998-03-26 |
2001-05-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of human mdm2 expression
|
|
EP1078053B1
(en)
*
|
1998-05-14 |
2005-09-28 |
Coley Pharmaceutical GmbH |
METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
|
|
CN1317009A
(zh)
*
|
1998-08-03 |
2001-10-10 |
东卡罗来纳大学 |
低腺苷反义寡核苷酸制剂、组合物、试剂盒及处理
|
|
JP2002524473A
(ja)
*
|
1998-09-09 |
2002-08-06 |
ジエンザイム コーポレイション |
プラスミドベクターのメチル化
|
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
|
US6214986B1
(en)
*
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
|
US6172216B1
(en)
*
|
1998-10-07 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of BCL-X expression
|
|
US5959097A
(en)
*
|
1998-11-20 |
1999-09-28 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of MEK2 expression
|
|
US5977341A
(en)
*
|
1998-11-20 |
1999-11-02 |
Isis Pharmaceuticals Inc. |
Antisense modulation of inhibitor-kappa B kinase-beta expression
|
|
US5962673A
(en)
*
|
1998-11-20 |
1999-10-05 |
Isis Pharmaceuticals Inc. |
Antisense modulation of inhibitor-kappa B kinase-alpha expression
|
|
US5981732A
(en)
*
|
1998-12-04 |
1999-11-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-13 expression
|
|
US6140124A
(en)
*
|
1999-04-06 |
2000-10-31 |
Isis Pharmaceuticals Inc. |
Antisense modulation of P38 mitogen activated protein kinase expression
|
|
US20040171566A1
(en)
*
|
1999-04-06 |
2004-09-02 |
Monia Brett P. |
Antisense modulation of p38 mitogen activated protein kinase expression
|
|
BR0006019A
(pt)
*
|
1999-04-06 |
2001-03-13 |
Univ East Carolina |
Oligonucleotìdeo de anti-sentido de adenosina baixo, composições, kit & método para tratamento de distúrbios de vias aéreas associados com broncoconstricção, inflamação pulmonar, alergia(s) & depleção de surfactante
|
|
US8143386B2
(en)
*
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
|
US6013788A
(en)
*
|
1999-04-09 |
2000-01-11 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Smad3 expression
|
|
US6046321A
(en)
*
|
1999-04-09 |
2000-04-04 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-i1 expression
|
|
DE19935756A1
(de)
*
|
1999-07-27 |
2001-02-08 |
Mologen Forschungs Entwicklung |
Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
|
|
WO2001012804A2
(en)
*
|
1999-08-13 |
2001-02-22 |
Hybridon, Inc. |
MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
|
|
EP1496121A3
(en)
*
|
1999-08-13 |
2005-02-09 |
Hybridon, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
|
JP2003510370A
(ja)
*
|
1999-10-07 |
2003-03-18 |
コリクサ コーポレイション |
Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓの融合タンパク質
|
|
CA2291367A1
(en)
*
|
1999-12-06 |
2001-06-06 |
Isabelle Henry |
Genetic constructions having a reduced or an increased number of epigenetic control regions and methods of use thereof
|
|
AU2001227889A1
(en)
|
2000-01-14 |
2001-07-24 |
The United States of America, represented by The Secretary, Department of Health & Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
|
PL209127B1
(pl)
|
2000-02-23 |
2011-07-29 |
Smithkline Beecham Biolog |
Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka
|
|
AU2001241738A1
(en)
*
|
2000-02-25 |
2001-09-03 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
US20040006036A1
(en)
*
|
2000-04-12 |
2004-01-08 |
Gmr, A Delaware Corporation |
Silencing transcription by methylation
|
|
NZ522755A
(en)
|
2000-05-19 |
2004-05-28 |
Corixa Corp |
Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds being administered in absence of exogenous antigen
|
|
AU6867801A
(en)
*
|
2000-06-20 |
2002-01-02 |
Corixa Corp |
Fusion proteins of mycobacterium tuberculosis
|
|
EP1319069B1
(en)
|
2000-06-28 |
2008-05-21 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
|
AU9475001A
(en)
*
|
2000-09-26 |
2002-04-08 |
Hybridon Inc |
Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
|
|
WO2002069369A2
(en)
*
|
2000-12-08 |
2002-09-06 |
Coley Pharmaceutical Gmbh |
Cpg-like nucleic acids and methods of use thereof
|
|
GB0105360D0
(en)
*
|
2001-03-03 |
2001-04-18 |
Glaxo Group Ltd |
Chimaeric immunogens
|
|
US7105495B2
(en)
*
|
2001-04-30 |
2006-09-12 |
Idera Pharmaceuticals, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
|
CA2446788A1
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
|
AU2002345847B2
(en)
*
|
2001-06-21 |
2008-05-29 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same
|
|
US7785610B2
(en)
*
|
2001-06-21 |
2010-08-31 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—III
|
|
US7354909B2
(en)
|
2001-08-14 |
2008-04-08 |
The United States Of America As Represented By Secretary Of The Department Of Health And Human Services |
Method for rapid generation of mature dendritic cells
|
|
DK1567641T3
(da)
|
2001-08-24 |
2012-08-27 |
Uvic Industry Partnerships Inc |
Proaerolysin indeholdende proteaseaktiveringssekvenser og fremgangsmåder til anvendelse til behandling af prostatacancer.
|
|
JP4601956B2
(ja)
*
|
2001-09-20 |
2010-12-22 |
グラクソ グループ リミテッド |
Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン
|
|
US7514414B2
(en)
|
2001-09-24 |
2009-04-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Suppressors of CpG oligonucleotides and methods of use
|
|
US7514415B2
(en)
|
2002-08-01 |
2009-04-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
|
|
WO2003035836A2
(en)
*
|
2001-10-24 |
2003-05-01 |
Hybridon Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
|
|
US7276489B2
(en)
*
|
2002-10-24 |
2007-10-02 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
|
|
ES2388968T3
(es)
*
|
2001-11-02 |
2012-10-22 |
Giuliani International Limited |
Inhibidores de Smad7 para el tratamiento de enfermedades del SNC
|
|
DK1581119T3
(da)
|
2001-12-17 |
2013-05-13 |
Corixa Corp |
Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
|
|
AU2002366710A1
(en)
|
2001-12-20 |
2003-07-09 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
|
|
AU2003203079B9
(en)
*
|
2002-02-04 |
2009-01-15 |
Oncothyreon Inc. |
Immunostimulatory, covalently lipidated oligonucleotides
|
|
WO2003070187A2
(en)
*
|
2002-02-15 |
2003-08-28 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
|
US8043622B2
(en)
|
2002-10-08 |
2011-10-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
|
|
DK1589934T3
(en)
|
2003-01-06 |
2015-12-21 |
Corixa Corp |
Certain AMINOAL COOLER GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND APPLICATION
|
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
|
US7354907B2
(en)
|
2003-02-07 |
2008-04-08 |
Idera Pharmaceuticals, Inc. |
Short immunomodulatory oligonucleotides
|
|
ITRM20030149A1
(it)
|
2003-04-02 |
2004-10-03 |
Giuliani Spa |
Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
|
|
WO2004087203A2
(en)
*
|
2003-04-02 |
2004-10-14 |
Coley Pharmaceutical Group, Ltd. |
Immunostimulatory nucleic acid oil-in-water formulations for topical application
|
|
AU2004275876B2
(en)
|
2003-09-25 |
2011-03-31 |
Coley Pharmaceutical Gmbh |
Nucleic acid-lipophilic conjugates
|
|
BRPI0416079A
(pt)
*
|
2003-10-30 |
2007-01-02 |
Coley Pharm Gmbh |
análogos de oligonucleotìdeos de classe c com uma potência imunoestimuladora aumentada
|
|
US8895521B2
(en)
|
2004-05-06 |
2014-11-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods and compositions for the treatment of uveitis
|
|
EP2497831B1
(en)
|
2004-05-25 |
2014-07-16 |
Oregon Health and Science University |
TB vaccination using HCMV-based vaccine vectors
|
|
GB0427131D0
(en)
*
|
2004-12-10 |
2005-01-12 |
Glaxosmithkline Biolog Sa |
Novel combination
|
|
WO2006065751A2
(en)
|
2004-12-13 |
2006-06-22 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
|
CA2602637A1
(en)
|
2005-03-31 |
2006-10-05 |
Glaxosmithkline Biologicals Sa |
Vaccines against chlamydial infection
|
|
PL2457926T3
(pl)
|
2005-04-29 |
2015-03-31 |
Glaxosmithkline Biologicals Sa |
Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis
|
|
EP1891093B1
(en)
|
2005-06-14 |
2011-03-23 |
Protox Therapeutics Incorporated |
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
|
|
MX2009003398A
(es)
|
2006-09-27 |
2009-08-12 |
Coley Pharm Gmbh |
Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
|
|
MX2009010800A
(es)
|
2007-04-04 |
2010-01-29 |
Infectious Disease Res Inst Id |
Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
|
|
PE20090146A1
(es)
*
|
2007-04-20 |
2009-03-23 |
Glaxosmithkline Biolog Sa |
Composicion inmunogenica contra el virus influenza
|
|
DK2170384T3
(en)
|
2007-07-02 |
2016-07-25 |
Etubics Corp |
METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
|
|
BRPI0820270A2
(pt)
|
2007-11-07 |
2015-06-16 |
Celldex Therapeutics Inc |
Anticorpo monoclonal, vetor de expressão, célula, conjugado molecular, composição, uso da composição, método para detectar a presença ou ausência de dec-205 em uma amostra biológica, e, uso de um conjugado molecular.
|
|
WO2009079796A1
(en)
|
2007-12-24 |
2009-07-02 |
Id Biomedical Corporation Of Quebec |
Recombinant rsv antigens
|
|
WO2009143292A2
(en)
|
2008-05-21 |
2009-11-26 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating pneumoconiosis with oligodeoxynucleotides
|
|
CN102325790A
(zh)
|
2008-12-03 |
2012-01-18 |
西马生物医学计划公司 |
应用酚可溶性调控蛋白研制疫苗
|
|
WO2010149743A2
(en)
|
2009-06-24 |
2010-12-29 |
Id Biomedical Corporation Of Quebec |
Vaccine
|
|
AU2010264688A1
(en)
|
2009-06-24 |
2012-01-19 |
Glaxosmithkline Biologicals S.A. |
Recombinant RSV antigens
|
|
SI3178490T1
(sl)
|
2009-07-15 |
2022-08-31 |
Glaxosmithkline Biologicals S.A. |
Sestavki proteina F RSV-ja in postopki za pripravo le-teh
|
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
|
WO2011101332A1
(en)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
|
KR101958753B1
(ko)
|
2010-04-13 |
2019-03-15 |
셀덱스 쎄라퓨틱스, 인크. |
인간 ｃｄ27에 결합하는 항체 및 이의 용도
|
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
|
ES2859673T3
(es)
|
2010-11-08 |
2021-10-04 |
Infectious Disease Res Inst |
Vacunas que comprenden polipéptidos de nucleósido hidrolasa no específica y esterol 24-c-metiltransferasa (SMT) para el tratamiento y el diagnóstico de la leishmaniasis
|
|
EP2505640A1
(en)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Vaccine compositions for birnavirus-borne diseases
|
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
|
SI3275892T1
(sl)
|
2011-05-13 |
2020-06-30 |
Glaxosmithkline Biologicals S.A. |
Prefuzijski RSV F antigeni
|
|
MX2013013627A
(es)
|
2011-06-21 |
2014-04-25 |
Oncofactor Corp |
Composiciones y metodos para la terapia y diagnostico de cancer.
|
|
EP2666785A1
(en)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Complement component C5a-based vaccine
|
|
WO2014042780A1
(en)
|
2012-08-03 |
2014-03-20 |
Infectious Disease Research Institute |
Compositions and methods for treating an active mycobacterium tuberculosis infection
|
|
JP2015525794A
(ja)
|
2012-08-06 |
2015-09-07 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
|
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
|
EP2703483A1
(en)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 peptide vaccine
|
|
SMT202400297T1
(it)
|
2013-03-13 |
2024-09-16 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services |
Proteine f del rsv pre-fusione e loro uso
|
|
EP3608332B1
(en)
|
2013-03-15 |
2022-06-01 |
GlaxoSmithKline Biologicals SA |
Vaccine against human rhinovirus
|
|
EP2978447B1
(en)
|
2013-03-28 |
2019-05-08 |
Infectious Disease Research Institute |
Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
|
|
CA2919773A1
(en)
|
2013-08-05 |
2015-02-12 |
Glaxosmithkline Biologicals S.A. |
Combination immunogenic compositions
|
|
EP2952893A1
(en)
|
2014-06-04 |
2015-12-09 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Method for detecting antibody-secreting B cells specific for HLA
|
|
CN106659777A
(zh)
|
2014-06-13 |
2017-05-10 |
葛兰素史密丝克莱恩生物有限公司 |
免疫原性组合产品
|
|
MA40920A
(fr)
|
2014-11-07 |
2017-09-12 |
Takeda Vaccines Inc |
Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
|
|
AU2015252119A1
(en)
|
2014-11-07 |
2016-05-26 |
Takeda Vaccines, Inc. |
Hand, foot, and mouth vaccines and methods of manufacture and use thereof
|
|
WO2016097865A1
(en)
|
2014-12-19 |
2016-06-23 |
Regenesance B.V. |
Antibodies that bind human c6 and uses thereof
|
|
JP6647315B2
(ja)
|
2015-01-09 |
2020-02-14 |
イーチュービクス コーポレイション |
組み合わせ免疫療法のための方法および組成物
|
|
CA2977493C
(en)
|
2015-03-03 |
2023-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Display platform from bacterial spore coat proteins
|
|
EP3268037B1
(en)
|
2015-03-09 |
2022-08-31 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
EP3286213B1
(en)
|
2015-04-20 |
2021-08-04 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
MX375989B
(es)
|
2015-05-26 |
2025-03-07 |
Ohio State Innovation Foundation |
Estrategia de vacuna basada en nanoparticulas contra el virus de la influenza porcina.
|
|
LU92821B1
(en)
|
2015-09-09 |
2017-03-20 |
Mologen Ag |
Combination comprising immunostimulatory oligonucleotides
|
|
GB2542425A
(en)
|
2015-09-21 |
2017-03-22 |
Mologen Ag |
Means for the treatment of HIV
|
|
EP3445783A2
(en)
|
2016-04-18 |
2019-02-27 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human cd40 and uses thereof
|
|
US20200148729A1
(en)
|
2016-05-21 |
2020-05-14 |
Infectious Disease Research Institute |
Compositions and Methods for Treating Secondary Tuberculosis and Nontuberculosis Mycobacterium Infections
|
|
AU2017268822B2
(en)
|
2016-05-27 |
2020-03-26 |
Etubics Corporation |
Neoepitope vaccine compositions and methods of use thereof
|
|
US11801290B2
(en)
|
2016-09-16 |
2023-10-31 |
Access To Advanced Health Institute |
Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
|
CA3043790A1
(en)
|
2016-12-16 |
2018-06-21 |
Institute For Research In Biomedicine |
Novel recombinant prefusion rsv f proteins and uses thereof
|
|
WO2018162450A1
(en)
|
2017-03-06 |
2018-09-13 |
Fundación Para La Investigación Médica Aplicada |
New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
|
|
IL269904B2
(en)
|
2017-04-19 |
2025-10-01 |
Inst Res Biomedicine |
Plasmodium sporozoite NPDP peptides as a vaccine and target for novel malaria vaccines and antibody binding
|
|
KR102673794B1
(ko)
|
2017-06-15 |
2024-06-11 |
액세스 투 어드밴스드 헬스 인스티튜트 |
나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
|
|
WO2019035963A1
(en)
|
2017-08-16 |
2019-02-21 |
Ohio State Innovation Foundation |
NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
|
|
US11648304B2
(en)
|
2017-11-03 |
2023-05-16 |
Takeda Vaccines, Inc. |
Zika vaccines and immunogenic compositions, and methods of using the same
|
|
CN111836639A
(zh)
|
2018-01-26 |
2020-10-27 |
河谷细胞有限公司 |
用于联合癌症疫苗和免疫辅助疗法的组合物和方法
|
|
CN112166118B
(zh)
|
2018-03-22 |
2025-07-11 |
德克萨斯大学体系董事会 |
治疗自身免疫性疾病和癌症的可溶性白介素-7受体(sIL7R)调节疗法
|
|
MX2020010913A
(es)
|
2018-04-17 |
2021-01-08 |
Celldex Therapeutics Inc |
Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.
|
|
US20230310323A1
(en)
|
2020-09-04 |
2023-10-05 |
Access To Advanced Health Institute |
Co-lyophilized rna and nanostructured lipid carrier
|
|
US20240417459A1
(en)
|
2021-04-09 |
2024-12-19 |
Celldex Therapeutics, Inc. |
Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
|
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
|
CN118510790A
(zh)
|
2021-12-13 |
2024-08-16 |
美国政府(由卫生和人类服务部的部长所代表) |
噬菌体λ-疫苗系统
|
|
CA3266697A1
(en)
|
2022-09-09 |
2024-03-14 |
Access To Advanced Health Inst |
COMPOSITION OF AN IMMUNOGENEOUS VACCINE CONTAINING A SAPONIN
|
|
KR20250167153A
(ko)
|
2023-03-03 |
2025-11-28 |
셀덱스 쎄라퓨틱스, 인크. |
항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물
|